ORIGINAL RESEARCH

Direct oral anticoagulants versus vitamin K antagonists in patients with antiphospholipid syndrome: systematic review and meta-analysis

Nazariy Koval,1 Mariana Alves,2,3,4 Rui Plácido,5,6 Ana G Almeida,5,6 João Eurico Fonseca,4,7 Joaquim J Ferreira,2,4,8 Fausto J Pinto,5,6 Daniel Caldeira2,5,6

ABSTRACT

Background  Despite vitamin K antagonists (VKA) being the gold standard in the prevention of thromboembolic events in antiphospholipid syndrome (APS), non-vitamin K antagonists oral anticoagulants/direct oral anticoagulants (DOACs) have been used off-label. Objective  We aimed to perform a systematic review comparing DOACs to VKA regarding prevention of thromboembolic events, occurrence of bleeding events and mortality in patients with APS. Methods  An electronic database search was performed through MEDLINE, CENTRAL and Web of Science. After data extraction, we pooled the results using risk ratio (RR) and 95% CI. Heterogeneity was assessed using the I². The outcomes considered were all thromboembolic events as primary, and major bleeding, all bleeding events and mortality as secondary. Evidence confidence was assessed using the Grading of Recommendations Assessment, Development and Evaluation methodology. Results  We included 7 studies and a total of 835 patients for analyses. Thromboembolic events were significantly increased in DOACs arm, compared with VKA—RR 1.69, 95% CI 1.09 to 2.62, P=—24%, n=719, 6 studies. In studies using exclusively rivaroxaban, which was the most representative drug in all included studies, the thromboembolic risk was increased threefold (RR 3.36, 95% CI 1.53 to 7.37). The risks of major bleeding, all bleeding events and mortality were not significantly different from control arm. The grade of certainty of our results is very low. Conclusions  Current evidence suggests DOACs use, particularly rivaroxaban, among patients with APS, is less effective than VKA since it is associated with 69% increased risk of thromboembolic events. 

INTRODUCTION

Antiphospholipid syndrome (APS) is an acquired autoimmune disease defined by the association of thromboembolic events (venous, arterial or microvascular) and/or pregnancy morbidity and the persistent presence of antiphospholipid (aPL) antibodies, such as lupus anticoagulant, anticardiolipin and anti-β2-glycoprotein 1.1,2 Triple-positive patients, who show a worse prognosis, represent less than 50% of those positive for one or two tests.3 A previous systematic review suggests that aPL antibodies were detected in 6% of women with pregnancy morbidity, in 13.5% of patients with stroke/transient ischaemic attack (TIA), 11% with myocardial infarction (MI) and 9.5% with deep vein thrombosis.4 Therefore, being thromboembolic diseases of major concern due to their high prevalence and often fatal consequences,5 the diagnosis and prognosis of APS should not be underestimated and treated accordingly.

Vitamin K antagonists (VKA) have been the gold standard in the primary and secondary prevention of thromboembolic events in APS.
The target international normalised ratios (INR) interval should be between 2.0 and 3.0, but long-term treatment is a great medical challenge in these patients, particularly due to the risk of major bleeding.6 7

Another class of anticoagulants, the non-vitamin K antagonists oral anticoagulants (NOACs), also called direct oral anticoagulants (DOACs), have been used in many countries worldwide in the treatment and prevention of venous thromboembolism (VTE) as well as in stroke prevention in atrial fibrillation. DOACs include drugs such as apixaban, edoxaban, dabigatran and rivaroxaban.8 DOACs revealed several advantages over VKA: lower incidence of major bleeding, minor drug and food interactions, rapid onset (and also offset) of action, more predictable pharmacokinetics and pharmacodynamics and lack of need for laboratory monitoring with higher patients’ satisfaction.8–10

On the other hand, the data and the experience in this area are limited and heterogeneous increasing the uncertainty about the use of DOACs in APS.

Therefore, we aimed to perform a systematic review to compare DOACs to VKA regarding prevention of thromboembolic events, occurrence of bleeding events and mortality in patients with APS.

METHODS
This systematic review followed the principles of MOOSE and PRISMA11 12 and was registered in PROSPERO: CRD42020216178.

Eligibility criteria
We considered published longitudinal studies (randomised controlled trials (RCTs) and observational studies, whether retrospective or prospective) comparing DOACs with VKA control group in adult patients diagnosed with APS. The type of APS (primary vs secondary), previously registered thromboembolic events (venous, arterial or microvascular) or the aPL antibodies profile were not initially relevant for the eligibility criteria. The outcomes considered were all thromboembolic events as primary, and major bleeding, all bleeding events and mortality as secondary. As rule, our all bleeding events encompass any type of bleeding, either major, clinically relevant non-major or minor.

Reviews, case series, case reports, commentaries or studies with unclear outcomes were not included.

Information sources and search strategies
An electronic database search for relevant material for inclusion criteria through MEDLINE, CENTRAL
### Table 1  Summary of study characteristics

<table>
<thead>
<tr>
<th>Identification</th>
<th>Study design</th>
<th>Country</th>
<th>Relevant patients</th>
<th>Intervention vs control</th>
<th>Follow-up</th>
<th>Mean age (SD)/ (IQR) years</th>
<th>Female (%)</th>
<th>Outcomes</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cohen et al&lt;sup&gt;13&lt;/sup&gt;</td>
<td>RCT</td>
<td>UK</td>
<td>116 adults, with thrombotic APS (venous), receiving standard-intensity warfarin: 3 months since the last event. Women, if fertile, with adequate contraception.</td>
<td>57 switched to Rivaroxaban (oral, one time a day, 20 mg, or 15 mg if creatinine clearance ≤29 mL/min) and 59 remained on Warfarin (target INR 2.0–3.0).</td>
<td>210 days.</td>
<td>Rivaroxaban—47 (17). Warfarin—50 (14).</td>
<td>Rivaroxaban—42 (74%). Warfarin—42 (71%).</td>
<td>Primary: percentage change in endogenous thrombin potential from randomisation to day 42. Secondary: occurrence of TE and bleeding events to day 210, thrombin generation, markers of in-vivo coagulation activation, adherence to treatment and quality of life.</td>
</tr>
<tr>
<td>Goldhaber et al&lt;sup&gt;25&lt;/sup&gt;</td>
<td>Posthoc subgroup analysis</td>
<td>Worldwide</td>
<td>151 adult patients (with symptomatic, proximal DVT or PE in RE-COVER/RE-COVER II trials and additionally treated with AC for 3–12 months or with dabigatran during RE-COVER/RE-COVER II trials in RE-MEDY).</td>
<td>71 on Dabigatran (oral, two times a day, 150 mg) and 80 on Warfarin (INR range 2.0–3.0).</td>
<td>6 months in RE-COVER/RE-COVER II trials and 6–36 months in RE-MEDY.</td>
<td>Dabigatran —47.8 (14.9). Warfarin —47.4 (16.8).</td>
<td>Dabigatran—24 (33.8%). Warfarin—31 (38.7%).</td>
<td>Primary: efficacy: recurrent symptomatic and objectively verified venous thromboembolism or death associated with venous thromboembolism (or unexplained death in the placebo-control study). Secondary: major bleeding, clinically relevant non-major bleeding, all bleeding events.</td>
</tr>
<tr>
<td>Martinelli et al&lt;sup&gt;29&lt;/sup&gt;†</td>
<td>Prospective cohort</td>
<td>Italy</td>
<td>28 patients, with thrombotic APS (venous).</td>
<td>13 on Rivaroxaban (oral, two times a day, 15 mg for 21 days followed by 20 mg one time a day or 20 mg one time a day if switched from VKA) and 15 on VKA.</td>
<td>21.9 months (mean).</td>
<td>Rivaroxaban —46.2 (16.4). Warfarin —43.1 (15.8).</td>
<td>Rivaroxaban—4 (30.8%). VKA—5 (33.3 %).</td>
<td>Primary: recurrence of thrombosis. Secondary: major bleeding and clinically relevant non-major bleeding.</td>
</tr>
<tr>
<td>Pengo et al&lt;sup&gt;22&lt;/sup&gt;</td>
<td>RCT</td>
<td>Italy</td>
<td>120 adults, with APS positive for all 3 aPL tests (triple positivity) and history of thrombosis (arterial, venous and/or biopsy proven microthrombosis).</td>
<td>59 on rivaroxaban (oral, one time a day, 20 mg or 15 mg if creatinine clearance 30–50 mL/min) and 61 on warfarin (target INR 2.0–3.0).</td>
<td>611 days.</td>
<td>Rivaroxaban—46.5 (10.2). Warfarin—46.1 (13.2).</td>
<td>Rivaroxaban—39 (66%). Warfarin—38 (62%).</td>
<td>Primary: TE events, major bleeding and vascular death. Secondary: DVT, PE, intracerebral thrombosis, retinal thrombosis, peripheral or mesenteric artery thrombosis, small vessels thrombosis, AML, stroke/TIA, fatal bleeding, clinically overt bleeding, critical area bleeding, minor bleeding, compliance with treatment.</td>
</tr>
<tr>
<td>Malec et al&lt;sup&gt;30&lt;/sup&gt;</td>
<td>Prospective cohort</td>
<td>Poland</td>
<td>176 patients diagnosed with APS.</td>
<td>DOACs: 36 on rivaroxaban (one time a day, 20 mg), 42 on apixaban (two times a day, 5 mg) and 4 on dabigatran (two times a day, 150 mg). 94 on VKA (target INR 2.0–3.0).</td>
<td>51 months (median).</td>
<td>DOACs—44 (11). VKA—45 (13).</td>
<td>DOACs—69 (84%). VKA—77 (82%).</td>
<td>Primary: symptomatic TE events (venous or arterial), PE, SVT, stroke, TIA, MI. Secondary: major bleeding, clinically relevant non-major bleeding.</td>
</tr>
</tbody>
</table>

Continued
Table 1  Continued

<table>
<thead>
<tr>
<th>Identification</th>
<th>Study design</th>
<th>Country</th>
<th>Relevant patients</th>
<th>Intervention vs control</th>
<th>Follow-up</th>
<th>Mean age (SD)/ (IQR) years</th>
<th>Female (%)</th>
<th>Outcomes</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ordi-Ros et al²⁴</td>
<td>RCT</td>
<td>Spain</td>
<td>190 adults, with thrombotic APS (venous or arterial), and a positive aPL testing on 2 occasions at least 3 months apart.</td>
<td>95 on rivaroxaban (one time a day, 20 mg or 15 mg if creatinine clearance 30–49 mL/min/1.73 m² and 95 on VKA (target INR 2.0–3.0 or 3.1–4.0 if history of recurrent thrombosis).</td>
<td>36 months.</td>
<td>Rivaroxaban—47 (40–55). VKA—51 (38–63).</td>
<td>64.2%</td>
<td>Primary: new thrombotic events, major bleeding. Secondary: time to thrombosis, type of thrombotic event, non-major bleeding, CV death, changes in level of selected biomarkers.</td>
</tr>
<tr>
<td>Sato et al³¹</td>
<td>Retrospective cohort</td>
<td>Japan</td>
<td>54 patients, with APS.</td>
<td>18 on DOACs (5 on rivaroxaban, 12 on edoxaban and 1 on apixaban) and 36 on warfarin.</td>
<td>60 months (at most).</td>
<td>DOACs—47.7 (17.1). Warfarin—42.6 (13.4).</td>
<td>63.2%</td>
<td>Primary: event-free survival for 5 years (recurrence of arterial/ venous thrombosis and severe bleeding requiring hospitalisation and/or transfusion).</td>
</tr>
</tbody>
</table>

*Considering only patients with APS.
†Authors only present age at index thrombosis.

AC, acute myocardial infarction; aPL, antiphospholipid; APS, antiphospholipid syndrome; CV, cardiovascular; DOACs, direct oral anticoagulants; DVT, deep vein thrombosis; MI, myocardial infarction; PE, pulmonary embolism; RCT, randomised controlled trial; SVT, supraventricular tachycardia; TE, thromboembolism; TIA, transient ischaemic attack; VKA, vitamin K antagonists.

<table>
<thead>
<tr>
<th>Identification</th>
<th>Study design</th>
<th>Country</th>
<th>Relevant patients</th>
<th>Intervention vs control</th>
<th>Follow-up</th>
<th>Mean age (SD)/ (IQR) years</th>
<th>Female (%)</th>
<th>Outcomes</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ordi-Ros et al²⁴</td>
<td>RCT</td>
<td>Spain</td>
<td>190 adults, with thrombotic APS (venous or arterial), and a positive aPL testing on 2 occasions at least 3 months apart.</td>
<td>95 on rivaroxaban (one time a day, 20 mg or 15 mg if creatinine clearance 30–49 mL/min/1.73 m² and 95 on VKA (target INR 2.0–3.0 or 3.1–4.0 if history of recurrent thrombosis).</td>
<td>36 months.</td>
<td>Rivaroxaban—47 (40–55). VKA—51 (38–63).</td>
<td>64.2%</td>
<td>Primary: new thrombotic events, major bleeding. Secondary: time to thrombosis, type of thrombotic event, non-major bleeding, CV death, changes in level of selected biomarkers.</td>
</tr>
<tr>
<td>Sato et al³¹</td>
<td>Retrospective cohort</td>
<td>Japan</td>
<td>54 patients, with APS.</td>
<td>18 on DOACs (5 on rivaroxaban, 12 on edoxaban and 1 on apixaban) and 36 on warfarin.</td>
<td>60 months (at most).</td>
<td>DOACs—47.7 (17.1). Warfarin—42.6 (13.4).</td>
<td>63.2%</td>
<td>Primary: event-free survival for 5 years (recurrence of arterial/ venous thrombosis and severe bleeding requiring hospitalisation and/or transfusion).</td>
</tr>
</tbody>
</table>

*Considering only patients with APS.
†Authors only present age at index thrombosis.

AC, acute myocardial infarction; aPL, antiphospholipid; APS, antiphospholipid syndrome; CV, cardiovascular; DOACs, direct oral anticoagulants; DVT, deep vein thrombosis; MI, myocardial infarction; PE, pulmonary embolism; RCT, randomised controlled trial; SVT, supraventricular tachycardia; TE, thromboembolism; TIA, transient ischaemic attack; VKA, vitamin K antagonists.
(defined according to Sapporo criteria),1 triple-positive patients (<60% or ≥60%) and type of DOACs used (just rivaroxaban vs other DOACs = rivaroxaban).

Assessment of confidence in cumulative evidence
As recommended by the Grading of Recommendations Assessment, Development and Evaluation (GRADE) Working Group methodology, two reviewers independently (NK and MA) assessed all the critical outcomes in the following domains: risk of bias, inconsistency, indirectness, imprecision and publication bias.20 21 The confidence on the pooled evidence was graded as very low, low, moderate or high. The pooled relative risks, as well as absolute risk measures, and the confidence on the pooled evidence were reported in the summary of findings table.15

RESULTS
Included studies
The search showed 357 uploaded references and after removing all duplicates, 321 remained. Then, 305 were excluded for one of the following reasons: background article, wrong study design (the model designed for these studies did not meet our inclusion criteria), wrong drug, wrong population, wrong outcome, duplicate; and just 16 full-text articles were assessed for eligibility, 6 of which had a wrong study design, 2 were protocols of ongoing trials and 1 was a commentary to Pengo et al22 (figure 1).

More detailed late stage/full text exclusion criteria are available in online supplemental data 2.

Finally, seven studies published between 2016 and 2019 were included in quantitative synthesis: three open-label RCTs,22–24 one posthoc APS subgroup analysis (Goldhaber et al25 of three RCTs (RE-COVER,20 RE-COVER II27 and RE-MEDY28 trials)) evaluating dabigatran in the treatment and prevention of VTE and three cohort studies (two prospective29 30 and one retrospective).31

Overall, this review included 835 patients with APS—not all studies were clear about using or not the revised Sapporo criteria1 in diagnosing APS—, followed for a period range between 210 days and 60 months. Out of these, 395 constituted the intervention arm (64.3% women) and 440 the control arm (64.3% women). The mean age was similar in both groups, 44.0–47.8 years (64.3% women) and 44.0 the control arm (64.3% women). The mean period range between 210 days and 60 months. Out of these patients, 285 were taking rivaroxaban, 75 dabigatran, 43 apixaban and 12 Edoxaban.

Most trials had warfarin as control, with exception of Ordi-Ros et al31 and Malec et al32 trials, which do not specify the VKA used.

All studies provided data for the primary and/or secondary outcomes of this review, 22–25 29–31 but only those with at least one event in each arm contributed for the meta-analysis.

Overall, there were 74 TE events (primary outcome) in the included trials, corresponding 55% to arterial and 45% to venous thrombosis. Out of 43 registered events in DOACs arm, 28 (65%) were arterial, largely driven by MI and stroke/TIA, 7 and 20 events, respectively (online supplemental data 3). In VKA arm, despite venous predominance, 13 (42%) in 31 events were arterial, out of which 1 corresponded to MI and 8 to stroke/TIA (online supplemental data 3).

More detailed characteristics of the included studies can be seen in table 1.

Risk of bias
Regarding all the outcomes, three studies22–24 were classified as having some concerns and four25 29–31 as serious/high risk of bias (tables 2 and 3).

Three RCTs22–24 offer some bias concerns due to deviation from intended intervention. Even though these trials were overseen by independent committees or had blinded end point adjudication, they were open label to ensure optimum drug dosing, monitoring and management.

The study by Goldhaber et al25 presents high risk due to selective reporting bias, since it was a posthoc analysis of three RCTs and there is no previously registered protocol available.

The study by Martinelli et al29 has serious risk of bias due to confounding—patients’ aPL profile was not appropriately controlled for.

The study by Malec et al32 has serious risk of bias due to confounding (risk factors as arterial hypertension, dyslipidaemia and triple APS positivity were not adjusted among arms), selection of participants (for the intervention arm authors only comprised patients who preferred a NOAC/DOAC or had unstable anticoagulation with VKAs, defined as time to therapeutic range below 50% within the previous 6 months, not being clear about the remaining patients), missing data (duration of follow-up differed between arms—mean 45 months vs 62 months) and measurement of the outcomes (TE events, major bleeding and all bleeding events outcomes were assessed by clinicians aware of the intervention received by study participants).

In addition, the study by Sato et al31 has serious risk of bias in the classification of interventions (drug regimen—dosage, route of administration, frequency—is not well defined), measurement of outcomes and selection of reported results. Being a retrospective cohort, outcome assessors were aware of the interventions received.

Outcomes
Primary: TE events
Thromboembolic events were significantly increased in the DOACs arm, compared with the VKA arm—RR 1.69 95% CI 1.09 to 2.62; I²=24%; n=719; six studies (figure 2).
Secondary: major bleeding, all bleeding events and mortality

DOACs did not significantly increase the risk of major bleeding or mortality with RR 1.22 (95% CI 0.72 to 2.07; I²=0%; n=691; five studies) and RR 1.17 (95% CI 0.48 to 2.84; I²=0%; n=577; four studies), respectively (figure 2).

On the other hand, all bleeding events risk was non-significantly decreased in DOACs arm with RR 0.79 (95% CI 0.47 to 1.32; I²=66%; n=457; three studies) (figure 2).

Subgroup analysis

Although there was no statistical difference comparing RCTs to cohort studies, the magnitude of the increased risk of TE in the DOACs arm was superior in RCTs—RR 2.32, 95% CI 1.14 to 4.72; I²=49%; three studies (online supplemental data 4).

Regarding the certainty of APS diagnosis, there were no differences among the studies which mention the Sapporo criteria and the ones that do not (online supplemental data 4).

Studies including at least 60% of triple-positive patients presented higher risk of all bleeding events, compared with studies with <60% of triple positives, even though without achieving significant subgroup difference (RR 1.19 95% CI 1.03 to 1.36 vs RR 0.61 95% CI 0.41 to 0.90; p=0.03) (online supplemental data 4). There were no differences regarding other outcomes.

The exclusive use of rivaroxaban presented a statistically significant increased magnitude of effect regarding TE events (RR 3.36, 95% CI 1.53 to 7.37 vs RR 1.08, 95% CI 0.72 to 1.57).

Table 2 Risk of bias assessment (RCTs)—TE events, major bleeding, all bleeding events and mortality

<table>
<thead>
<tr>
<th>Study</th>
<th>Risk of bias arising from the randomisation process</th>
<th>Bias due to deviations from the intended interventions</th>
<th>Risk of bias due to missing outcome data</th>
<th>Risk of bias in measurement of the outcome</th>
<th>Risk of bias in selection of the reported result</th>
<th>Overall risk of bias</th>
</tr>
</thead>
<tbody>
<tr>
<td>Schulman et al (RE-COVER)26</td>
<td>Low risk</td>
<td>Low risk</td>
<td>Low risk</td>
<td>Low risk</td>
<td>Low risk</td>
<td>Low risk</td>
</tr>
<tr>
<td>Schulman et al (RE-COVER II)27</td>
<td>Low risk</td>
<td>Low risk</td>
<td>Low risk</td>
<td>Low risk</td>
<td>Low risk</td>
<td>Low risk</td>
</tr>
<tr>
<td>Schulman et al (RE-MEDY)28</td>
<td>Low risk</td>
<td>Low risk</td>
<td>Low risk</td>
<td>Low risk</td>
<td>Low risk</td>
<td>Low risk</td>
</tr>
<tr>
<td>Goldhaber et al25</td>
<td>Low risk</td>
<td>Some concerns</td>
<td>Low risk</td>
<td>Low risk</td>
<td>Some concerns</td>
<td>Some concerns</td>
</tr>
<tr>
<td>Cohen et al23</td>
<td>Low risk</td>
<td>Some concerns</td>
<td>Low risk</td>
<td>Some concerns (except for mortality—low)</td>
<td>Some concerns</td>
<td>Some concerns</td>
</tr>
<tr>
<td>Pengo et al22</td>
<td>Low risk</td>
<td>Some concerns</td>
<td>Low risk</td>
<td>Low risk</td>
<td>Some concerns</td>
<td>Some concerns</td>
</tr>
<tr>
<td>Ordi-Ros et al24</td>
<td>Low risk</td>
<td>Some concerns</td>
<td>Low risk</td>
<td>Low risk</td>
<td>Some concerns</td>
<td>Some concerns</td>
</tr>
</tbody>
</table>

Table 3 Risk of bias assessment (observational studies)—TE events, major bleeding, all bleeding events and mortality

<table>
<thead>
<tr>
<th>Study</th>
<th>Bias due to confounding</th>
<th>Bias in selection of participants</th>
<th>Bias due to deviations from the intended interventions</th>
<th>Bias due to missing data</th>
<th>Bias due to measurement of outcomes</th>
<th>Bias in selection of the reported result</th>
<th>Overall risk of bias</th>
</tr>
</thead>
<tbody>
<tr>
<td>Martinelli et al29</td>
<td>Serious risk</td>
<td>Low risk</td>
<td>Moderate risk</td>
<td>Low risk</td>
<td>Serious risk (except for mortality—low)</td>
<td>Serious risk (except for mortality—low)</td>
<td>Serious risk</td>
</tr>
<tr>
<td>Malec et al30</td>
<td>Serious risk</td>
<td>Serious risk</td>
<td>Low risk</td>
<td>Low risk</td>
<td>Serious risk (except for mortality—low)</td>
<td>Moderate risk (except for mortality—low)</td>
<td>Serious risk</td>
</tr>
<tr>
<td>Sato et al31</td>
<td>Moderate risk</td>
<td>Moderate risk</td>
<td>Serious risk</td>
<td>Low risk</td>
<td>Serious risk (except for mortality—low)</td>
<td>Serious risk (except for mortality—low)</td>
<td>Serious risk</td>
</tr>
</tbody>
</table>
Concerning TE events, the GRADE confidence is very low, being downgraded due to study design, risk of bias and imprecision (table 4). As for secondary outcomes, the GRADE confidence is also very low for the same reasons—except for all bleeding events, additionally downgraded due to indirectness (table 4).

Since we are combining RCTs with observational studies, the overall quality of evidence was assessed using the lowest quality of all included studies.

Separated GRADE analysis for RCTs and observational studies is available in online supplemental data 5. Considering only RCTs the GRADE is low, except for all bleeding events, which is very low.

**DISCUSSION**

Our systematic review showed that the use of DOACs, compared with VKA, increased the relative risk of thromboembolic events by 69% in APS. In the DOACs arm, most of the events were arterial (MI and stroke/TIA)—65%, suggesting that patients with APS with history of arterial thrombosis or with other risk factors for arterial thrombosis may not be good candidates...
for DOACs, in particular for rivaroxaban. The analyses including studies with more robust methodology, namely RCTs and studies with high APS diagnostic certainty, presented an even higher risk of TE events in DOACs arm with RR 2.42 and RR 3.18, respectively. Additionally, in studies using exclusively rivaroxaban, which was the most representative drug in all included studies, the thromboembolic risk triples, when compared with VKA.

The risk of major bleeding or mortality was increased without achieving statistical significance. All bleeding events risk was non-significantly decreased in the DOACs arm. However, studies with higher risk patients (≥60% triple positive) showed quite the opposite. Despite non-significant results, this outcome increased substantially the risk comparing to VKA, and this probably is related to the worse thromboembolic and haemorrhagic profile of the included patients. Also, it is important to refer that in our population, a large portion of relevant bleeding events among female patients on rivaroxaban were heavy menstrual bleedings, being congruous with already existing data.

Therefore, the results of this systematic review give scientific support to current recommendations for not recommending DOACs for secondary prevention of TE in patients with APS, VKA being the elected drug class in this context. Nevertheless, future data from observational studies and RCT will be important to clarify this risk/benefit in selected group of patients and different DOACs. For instance, ASTRO-APS trial with apixaban 5mg two times a day compared with warfarin in patients with APS with VTE might change our present approach to this class of drugs.

In contrast to atrial fibrillation treatment, where VKA demonstrated to be less efficacious and safe, the reason behind DOACs failure in APS is still not consensual. Unlike VKA, they target only one coagulation factor, either Xa or IIa, and whether directed anticoagulation is sufficient or not in patients with APS remains unclear. Theoretically, and having in mind the pathophysiology of this syndrome, the presence of aPL antibodies constitutes one plausible justification since they can interfere with the normal pharmacokinetics of these drugs. Due to the fact that aPL antibodies increase lag time and time to peak thrombin generation and lead to platelet hyper-activation and fibrinolysis impairment, they might be responsible for DOACs’ resistance in APS. Other possible drawbacks are suboptimal drug concentration demonstrated in animal models, as well as the short drug half-life that may lead to a fast decline of anticoagulation effect and treatment failure if administrations are missed.

Although meta-analyses on this topic have recently been published, our systematic review, in comparison, offers relevant advantages. Our focus was exclusively on patients with APS, without limiting TE events to either arterial, venous or microvascular. We included RCTs, which are known to better establish the causality,

<table>
<thead>
<tr>
<th>Outcome</th>
<th>Relative effect (95% CI)</th>
<th>Anticipated absolute effects (95% CI)</th>
<th>Certainty</th>
<th>What happens</th>
</tr>
</thead>
<tbody>
<tr>
<td>Thromboembolic events</td>
<td>RR 1.69 (1.09 to 2.62)</td>
<td>VKA 8.1% (8.9 to 21.3) DOACs 13.8%</td>
<td>Very low*</td>
<td>DOACs may increase the occurrence of thromboembolic events but the evidence is very uncertain.</td>
</tr>
<tr>
<td>Major bleeding</td>
<td>RR 1.22 (0.72 to 2.07)</td>
<td>VKA 6.6% (4.7 to 13.6) DOACs 8.0%</td>
<td>Very low†</td>
<td>DOACs may increase the occurrence of major bleeding but the evidence is very uncertain.</td>
</tr>
<tr>
<td>All bleeding events</td>
<td>RR 0.79 (0.47 to 1.32)</td>
<td>VKA 32.5% (15.3 to 42.9) DOACs 25.7%</td>
<td>Very low‡</td>
<td>DOACs may decrease the occurrence of all bleeding events but the evidence is very uncertain.</td>
</tr>
<tr>
<td>Mortality</td>
<td>RR 1.17 (0.48 to 2.84)</td>
<td>VKA 2.7% (1.3 to 7.7) DOACs 3.2%</td>
<td>Very low§</td>
<td>The effect of DOACs on mortality is very uncertain.</td>
</tr>
</tbody>
</table>

*Three RCTs classified as having some concerns and three cohort studies at serious risk of bias.
†RR 1.22 (95% CI 0.72 to 2.07).
‡I²=66%.
§Mostly no direct comparison.
**RR 1.17 (95% CI 0.48 to 2.84).
††The risk in the intervention group (and its 95% CI) is based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI).

DOACs, direct oral anticoagulants; RR, risk ratio; VKA, vitamin K antagonists.
between drugs and outcomes, and also observational studies, whose results provided data on all four existing DOACs and less strict APS population. Our pooled data also provide objective measure of the DOACs risk in APS as results achieved statistical significance concerning TE events, supporting some expert consensus.

There are some limitations regarding our review that should be taken into account. First, not all included studies were clear about using or not the revised Sapporo criteria in diagnosing APS. To overcome this limitation, we performed a subgroup analysis that did not show differences between studies with more or less restricting inclusion criteria. Second, approximately 67% of our population was on rivaroxaban, which could bias our conclusions. Indeed, in the subgroup analysis, in studies with heterogeneous use of DOACs the significant effect of TE events was lost. Third, the grade of certainty of our results is very low, due to methodological issues of the studies analysed. However, the inclusion of observational studies is important and offers some relevant advantages, such as a more diversified DOACs samples and the use of well-defined inclusion criteria, contributing to a more homogeneous population.

This is the best evidence available and until more robust evidence is published, physicians need to choose which drug benefits the most their patients based on this reality.

Currently, two more RCTs are ongoing: ASTRO-APS (apixaban for secondary prevention of TE among patients with APS) and RISAPS (rivaroxaban for patients who had stroke with APS, with or without SLE), follows the results of RAPS trial, with estimated completion dates for 2021 and 2023, respectively. The ASTRO-APS will include only a strict set of patients with APS with history of venous TE. In this study, patients with previous arterial thrombosis were excluded as these events may be a marker of higher thrombogenicity, recurrent events and potential DOACs treatment non-response. The RISAPS trial aims to study higher intensity anticoagulation with rivaroxaban (15 mg, two times a day, a dose recommended for the acute treatment of VTE) and warfarin (target INR 3.5)—these being the novelties of this study.

Notwithstanding our data, the ongoing trials, despite the existing differences in the population (stricter in ATRO-APS), will inform more robustly about the possible class effect of DOACs in APS. The need of further trials depends on these results.

In conclusion, our review suggests that DOACs use, particularly rivaroxaban, among patients with APS, appears to be less effective than VKA, since it is associated with increased risk of thromboembolic events. In fact, some authors report patients, mostly triple-positive, who experienced catastrophic APS—microthromboses involving at least three organs within a week after rivaroxaban introduction. Despite our results advising against DOACs, particularly rivaroxaban, judgements concerning other DOACs should be more watchful considering the ongoing trials, namely ASTRO-APS, that might provide additional data on this regard and consequently change the present approach to this class of drugs in patients with APS.

REFERENCES


Koval N, et al. RMD Open 2021;7:e001678. doi:10.1136/rmdopen-2021-001678


